Neoadjuvant Nivolumab plus Chemotherapy for Resectable Non-Small Cell Lung Cancer in CheckMate 816: 3-Year Update and Outcomes by Definitive Surgery Status

Jessica Donington

Invited Discussant

Jessica S. Donington, MD, MSCR, is a thoracic surgeon with focus on the comprehensive and multidisciplinary care of benign and malignant chest diseases. Dr. Donington specializes in non-small cell lung cancer and treats people at all stages, providing a personalized approach to diagnosis and treatment using the latest technology and innovations.

In addition to her clinical practice, Dr. Donington is an avid researcher and respected leader in her field. Her research focus is on novel biomarkers for early detection and treatment of lung cancer and clinical trials that incorporate surgery into multi-modality lung cancer care.

Dr. Donington is a past president of Women in Thoracic Surgery, New York Society for Thoracic Surgery and Western Thoracic Surgical Association. She is a member of the American Board of Thoracic Surgery  and serves on the editorial boards for the Annals of Thoracic Surgery, Journal of Thoracic Oncology and CHEST. 

Stephen Broderick

Abstract Presenter

Dr. Stephen R. Broderick MD, MPHS is a thoracic surgeon at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Centerand Sibley Memorial Hospital.  After graduation from the Georgetown University School of Medicine he completed a residency in general surgery at the Weill Cornell New York Presbyterian Hospital.  During residency he dedicated two years to thoracic oncology research at Memorial Sloan Kettering Cancer Center.  His work at MSKCC focused on DNA copy number and gene expression changes in lung adenocarcinoma and was included in The Cancer Genome Atlas.  Following residency he completed a fellowship in cardiothoracic surgery at Washington University in St. Louis.  Dr Broderick’s academic interests include thoracic surgery clinical outcomes and perioperative applications of systemic therapy for NSCLC.  His clinical interests include thoracic surgical oncology as well as the breadth of benign conditions of the chest and foregut.